![]() | ![]() |
Formats:
|
||||||||||||||||||
Copyright © 2008 by The Endocrine Society DEAD-Box Protein-103 (DP103, Ddx20) Is Essential for Early Embryonic Development and Modulates Ovarian Morphology and Function Departments of Obstetrics and Gynecology (J.-F.M., X.Y., Q.O., L.J., Y.S.), Cell Biology and Physiology (J.-F.M., X.Y., Q.O., L.J., Y.S.), Pediatrics (L.J.M.), Molecular Biology and Pharmacology (L.J.M.), and Medicine (P.A.C.), Washington University School of Medicine, St. Louis, Missouri 63110 aJ.-F.M. and X.Y. contributed equally to this work. Address all correspondence to: Yoel Sadovsky, M.D., Magee Womens Research Institute, 204 Craft Avenue, Pittsburgh, Pennsylvania 15213. E-mail: ysadovsky/at/mwri.magee.edu. Received September 7, 2007; Accepted January 25, 2008. This article has been cited by other articles in PMC.Abstract The DEAD-box helicase DP103 (Ddx20, Gemin3) is a multifunctional protein that interacts with Epstein-Barr virus nuclear proteins (EBNA2/EBNA3) and is a part of the spliceosomal small nuclear ribonucleoproteins complex. DP103 also aggregates with the micro-RNA machinery complex. We have previously shown that DP103 interacts with the nuclear receptor steroidogenic factor-1 (SF-1, NR5A1), a key regulator of reproductive development, and represses its transcriptional activity. To further explore the physiological function of DP103, we disrupted the corresponding gene in mice. Homozygous Dp103-null mice die early in embryonic development before a four-cell stage. Although heterozygous mice are healthy and fertile, analysis of steroidogenic tissues revealed minor abnormalities in mutant females, including larger ovaries, altered estrous cycle, and reduced basal secretion of ACTH. Our data point to diverse functions of murine DP103, with an obligatory role during early embryonic development and also in modulation of steroidogenesis. THE NUCLEAR RECEPTOR steroidogenic factor-1 (SF-1, NR5A1) is essential for development of steroid-producing glands and the ventromedial hypothalamus. SF-1 also controls the expression of diverse enzymes involved in the biosynthesis of steroid hormones and coregulates the function of pituitary gonadotropes (reviewed in Refs. 1,2,3). Inactivating mutations in the Sf-1 gene cause sex reversal and severe endocrine dysfunction in rodents and humans. Akin to other members of the nuclear receptor family, SF-1 harbors a conserved DNA-binding domain and a ligand-binding domain. Although considered an orphan receptor, discrete phospholipids were recently found to bind SF-1 and modulate its transcriptional activity (4,5). The activity of SF-1 is also modulated by posttranslational phosphorylation (6) as well as by direct protein-protein interactions with diverse proteins, including DAX-1, SOX9, WT1, GATA-4, Ptx1, ZIP67, GIOT-1, c-Jun, SNURF, and RIP140 (7,8,9,10,11,12,13,14,15,16,17). We previously identified a discrete domain within SF-1 that imparts transcriptional repression through the recruitment of DEAD-box protein-103 (DP103)/Gemin3/Ddx20, a member of the DEAD-box family of putative RNA helicases (18,19). We confirmed that DP103 acts as transcriptional repressor of SF-1, and this repression requires the C-terminal region that is also germane for DP103’s helicase activity (19). Additionally, DP103 causes sumoylation of SF-1 and relocalization to discrete nuclear foci (20). DP103 also represses the transcriptional activity of Egr2 (21) and FOXL2 (22) and mediates the transcriptional repression of the N-terminal repression domain of METS and both N- and C-terminal repression domains of ERF via recruitment of histone deacetylase proteins (23,24). Finally, consistent with the notion that RNA helicases are involved in multiple aspects of RNA metabolism, DP103 associates with the survival motor neuron (SMN) protein, which is required for the assembly of spliceosomal small nuclear ribonucleoproteins (25,26) (reviewed in Ref. 27). Although some of the molecular pathways of DP103 are known, little is known about the role of DP103 in development and physiology. To gain insight into the function of DP103 in vivo, we used homologous recombination to inactivate the Dp103 locus in mice. We found that homozygous Dp103-null mutant embryos die before implantation. Dp103 heterozygous mutant mice are viable and fertile. Further characterization of Dp103 heterozygotes with a primary focus on reproduction revealed several alterations in the endocrine system, consistent with the influence of DP103 on SF-1. Materials and Methods Mice and genotyping All experiments were approved by the Washington University Animal Studies Committee. Mice were maintained in the Washington University barrier animal facility. To create our transgene, a 7.5-kb fragment of the mouse Dp103 gene that contains exon 1 was excised from a 129/Sv BAC plasmid and subcloned into pSP72 (Promega, Madison, WI). The resultant plasmid was used as a recipient for recE/T-mediated recombination in Escherichia coli as described by Stewart and colleagues (28). The donor-targeting fragment for bacterial recombination included a disruptive knock-in cassette made of a 2.8-kb PCR product, generated from a plasmid harboring myc-tagged enhanced green fluorescent protein (EGFP) upstream of a loxP-flanked neomycin/kanamycin resistance cassette with a dual eukaryotic/prokaryotic (PGK/Tn5) promoter. This cassette was flanked by 66-bp arms that were homologous to Dp103. Recombinants were selected using appropriate antibiotics and confirmed by PCR and Southern blotting. The linearized vector was electroporated into 129/Sv embryonic stem (ES) cells, and two independent positive clones were obtained after selection with G418 and confirmed by Southern blotting with a probe outside the homology arms. The two ES clones were microinjected into C57BL/6 blastocysts to obtain chimeric mice. Resulting chimeras were bred with C57BL/6 mice, and offspring derived from ES cells were identified by their coat color, Southern blotting, and PCR of tail DNA. Genotyping was carried out by PCR using the following three primers: 5′-TTGACAACCTCCGAGTCCACTATGGCT, 5′-TTCCTCGTGCTTTACGGTATCGCCGCT, and 5′-ACTGATGCCACCAGATACCAAATA. For PCR screening of embryonic genotype, we used a DNA extraction kit (Epicenter Biotechnologies, Madison, WI). DNA was extracted from each embryo in 12 μl DNA extraction solution and processed following the manufacturer’s instructions. Embryo harvest Female mice heterozygous for Dp103 were generated after back-crossing into C57BL/6 background mice and were superovulated using ip injections of 5 IU equine gonadotropin, followed 48 h later by 5 IU human chorionic gonadotropin (both from Sigma Chemical Co., St. Louis, MO). The injected female mice were then placed with Dp103+/− males of proven fertility and checked the next morning for a copulation plug. Timing after human chorionic gonadotropin injection and mating was used to recover one-cell embryo (24 h), two-cell embryo (48 h), or morula (72 h). Embryos were flushed from dissected oviducts that were attached to the proximal end of the uterine horn under stereomicroscopy (Nikon SMZ-10A) using a blunted 30-gauge needle. The embryos were placed in warmed human tubal fluid medium (Irvine Scientific, Irvine, CA) supplemented with 0.25% BSA and 0.3 mg/ml hyaluronidase (Sigma) to remove the cumulus cells in one-cell embryos. Flushed embryos were placed on Superfrost Slides (Fisher Scientific, Waltham, MA), fixed in 3% paraformaldehyde for 20 min at room temperature, and processed as described. At least 10 pregnancies and more than 80 embryos were examined for Dp103−/− genotype at the different gestational ages. DP103 antibodies, immunofluorescence, and immunohistochemistry The production of anti-DP103 polyclonal antibodies was previously described (29). The antibody was affinity purified using an AminoLinkPlus kit (Pierce, Rockford, IL) and confirmed by electrophoresis. For detection of embryonic DP103 protein, 1- to 3-d embryos were permeabilized for 10 min in 0.1% Tween 20 in PBS. Fixed embryos were blocked for 1 h in 20% normal donkey serum, 0.5 mg/ml purified antimouse CD16/CD32 (BD Biosciences, San Jose, CA), and 2% BSA. The sections were incubated with anti-DP103 (stock concentration is 2.3 μg/μl, diluted to a working concentration of 1:100) or goat anti-GFP antibody (1:50; Santa Cruz Biotechnology, Santa Cruz, CA). After washing three times in PBS with 2% BSA, the specimens were incubated with antirabbit Alexa 594 or antigoat Alexa 488 (Invitrogen, Carlsbad, CA). Sections were counterstained with TOPRO-3 iodide (Invitrogen) at a concentration of 4 μm, washed three times in PBS, and mounted in Vectashield mounting medium (Vector Laboratories, Burlingame, CA). For histological assessment of DP103 expression, ovaries, testes, and adrenal glands were dissected from wild-type or Dp103+/− mice (6–12 wk old, virgins), weighed, and fixed in 4% paraformaldehyde in PBS overnight at 4 C. Sections were cut from paraffin-embedded tissues, mounted on Superfrost-plus slides, and after deparaffinization were subjected to antigen retrieval using 0.01 m sodium citrate (pH 6.0) in a microwave. After washes, the sections were blocked using 10% goat serum, 0.3% Triton X-100, and 1% BSA in Tris-buffered saline for 1 h. Rabbit anti-DP103 was diluted 1:100 in blocking buffer and incubated on sections overnight at 4 C. Fluorescent sections were washed and incubated with Alexa 488 antirabbit antibody (1:400; Invitrogen) for 1 h. Nuclei were stained using TOPRO-3 iodide (Invitrogen). Preimmune serum or absent primary antibody was used to confirm the specificity of the DP103 antibody. Ovarian follicles were analyzed using a single slide in a longitudinal midsection of each ovary by a researcher who was blinded to the genotype. After application of the secondary antibody, some ovarian sections were incubated with the ABC reagent (Vector) for 30 min and immunoreactivity visualized using AEC chromogen (Vector). RT-PCR Total RNA was isolated using Tri reagent (Sigma) following the manufacturer’s instructions, then incubated with DNase I (1 U/10 μg RNA; Ambion, Austin, TX) at 37 C for 20 min. For quantitative PCR, we initially performed RT with 0.5 μg total RNA in a 50-μl RT reaction that included 5 μl TaqMan RT buffer, 11 μl 25 mm MgCl2, 10 μl 10 mm dNTP mixture, 2.5 μl 50 μm random primer, 20 U RNase inhibitor, and 1.25 μl murine leukemia virus reverse transcriptase (Applied Biosystems, Foster City, CA). Transcript levels were determined by quantitative PCR using Geneamp 5700 or 7300 Sequence Detection System (Applied Biosystems). Each 50 μl of PCR included 3 μl RT products, 300 nm each of forward and reverse primers, and 25 μl SYBR-Green master mix (Applied Biosystems). Samples were normalized to parallel reactions using primers specific for 18S RNA as we previously described (30). The fold increase relative to control cultures was determined by the 2−ΔΔCT method (31). PCR amplification was performed with the following primers pairs: Cyp11a1, 5′-CCAGTGTCCCCATGCTCAA-3′ and 5′-CAGCTGCATGGTCCTTCCA-3′; StAR, 5′-GGAGATGCCGGAGCAGAGT-3′ and 5′-GCCAGTGGATGAAGCACCAT-3′; Cyp17a1, 5′-CCTGCACTTGGCAATACATCTG-3′ and 5′-AGGTCCCTCAACGTGGCATA-3′; Cyp19a1, 5′-CCACAGCTGAGAAACTGGAAGA-3′ and 5′-TCGTCAGGTCTCCACGTCTCT-3′; Cyp21a1, 5′-CCCGGGTTTTCTGCACTTC-3′ and 5′-TGTAGATGGGCCCGAGTTTC-3′; and 18S, 5′-CACGGCCGGTACAGTGAAA-3′ and 5′-AGAGGAGCGAGCGACCAA-3′. Examination of the estrous cycle The estrous cycle stage was determined by daily assessment of vaginal cytology over a period of 21 d. Animals were individually housed and given food and water ad libitum. Vaginal smears from four wild-type and four Dp103 heterozygous female mice (age 9–12 wk) were collected at 1000 h by investigators blinded to the mouse genotype. Scrapings were obtained using small cotton swabs prewetted with PBS, smeared onto a glass slide, fixed in absolute methanol, and stained with Giemsa (Sigma). The estrous cycle stage was determined by the presence of nucleated epithelial cells (NEC), cornified epithelial cells (CEC), and polymorphonuclear cells (PMN), with estrus enriched for CEC and some NEC without PMN, metestrus characterized by CEC and PMN, diestrus enriched for PMN with few NEC, and proestrus enriched mainly by NEC and few CEC and PMN. Ambiguous cycle status was ascertained based on determinations on the preceding and subsequent day and labeled as an intermediate value (32). Restraint test and hormone measurement Hormone levels were measured in the morning (2 h after lights on) and evening (1 h before lights off) serum samples as well as after morning restraint stress, performed by placing the mice in a 50-ml Falcon tube for 30 min as described by (33). Blood was collected from stressed and control mice, and plasma was separated by centrifugation and stored at −80 C until assay. Plasma concentrations of corticosterone (ICN, Costa Mesa, CA) and ACTH (Diasorin, Stillwater, MN) levels were measured as previously described (33). Statistics Each experiment was repeated at least three times. Significance was analyzed by Student’s t test, ANOVA with post hoc Bonferroni test, or χ2 test where appropriate and detailed in each figure legend (Primer of Biostatistics software package; McGraw-Hill, Inc., New York, NY). A value of P < 0.05 was determined significant. Results Expression of DP103 in steroid-producing tissues Because of the prominent expression of DP103 in steroid-producing organs and the interaction of DP103 with SF-1 (18,19,20), we focused our attention on DP103 expression in these tissues (Fig. 1 1).
Generation of Dp103 mutant mice To elucidate the function of DP103, we inactivated Dp103 gene by targeted gene disruption. Our construct was designed to replace the genomic fragment containing the first exon of the Dp103 gene with a disruptive myc-EGFP-neo cassette using homologous recombination (Fig. 2 2,
Minor perturbations in the ovaries of Dp103+/− mice We sought to determine whether Dp103+/− animals revealed DP103 haploinsufficiency in steroid-producing tissues that are modulated by SF-1 activity. When compared with wild-type mice, Dp103+/− females had heavier ovaries (Fig. 3A 3A).
Stress response in Dp103+/− mice Last, we explored the basal and stress levels of ACTH and corticosterone in Dp103+/− mice and their wild-type littermates. As shown in Fig. 6A 6A,
Discussion Our data reveal an essential role for murine DP103 during early embryonic development. We found that Dp103-null mice failed to develop beyond the two-cell stage. Although we did not uncover the cause of the early embryonic lethality, we noted that Dp103-null embryos could not enter a developmental phase that is associated with zygotic gene activation (ZGA), characterized by degradation of maternally inherited transcripts and transition to zygotic gene expression (39,40,41,42,43). Consistent with this observation, DP103 is among the proteins that are selectively up-regulated during ZGA in the two-cell embryo (44,45). Our findings that 1) haploid oocytes can develop even in the absence of DP103 (albeit at a lower rate compared with wild-type oocytes) and 2) Dp103-deficient, haploid oocytes were able to contribute to Dp103−/− zygotes suggest that germline-derived DP103 protein is not essential before ZGA and raises the speculation that DP103 is involved in the reprogramming that takes places during ZGA and enables embryonic development beyond the two-cell stage. DP103 harbors domains that are characteristic of DEAD-box RNA helicases. It also exhibits RNA/RNA and DNA/RNA helicase activity (19) and associates with proteins involved in RNA processing, such as Ago2 (29,46,47,48) and the SMN protein complex (25,26,49,50,51). The SMN-related complex is required for the assembly of spliceosomal small nuclear ribonucleoproteins (snRNPs) (52). Genetic ablation of murine Smn results in early embryonic lethality before entering the blastocyst stage (49). Similarly, genetic ablation of gemin2, another component of the SMN complex, results in survival beyond the blastocyst stage but preimplantation death (50). Together, these data suggest that the function of DP103 during early zygote development involves RNA processing and conceivably silencing of maternal transcripts. Unlike Dp103-null mice, heterozygous mice are viable, and although they exhibit several endocrine perturbations, these mice appear healthy and fertile. The relatively minor phenotype associated with Dp103 heterozygous mice is consistent with the observation that at least 70% of small interfering RNA-dependent depletion of DP103 protein is necessary to uncover a measurable effect on assembly of the core SMN complex (51,53,54). We focused our analysis on steroid-producing organs of Dp103 heterozygous mice because of previous findings by our group and others regarding the repression of SF-1 activity by DP103 (19,20). The role of this repression in the reproductive physiology is unknown. We found several endocrine alterations that were limited to the Dp103 heterozygous female. These included larger ovaries, a greater number of empty follicles or DP103-negative oocytes, a prolonged estrous phase, up-regulation of ovarian Cyp17a1 mRNA, and lower levels of basal nocturnal ACTH. Because Cyp17a1 regulates the synthesis of androstenedione, a steroid with androgenic properties (55), our data suggest that the increased occurrence of empty follicles in Dp103+/− mice may result from the perturbation of the delicate steroidogenic environment required for proper follicular development (56). Cyp17a1 is coexpressed with Cyp19a1 during the murine estrous cycle (57,58). The observation that the expression of Cyp19a1, as well as that of Cyp11a1 and steroid acute regulatory protein, is not enhanced in Dp103 heterozygotes suggests that the increase in Cyp17a1 mRNA is specific, and does not reflect a difference in the estrous cycle stage. Moreover, these observations suggest that the increase in size of the ovary in Dp103 heterozygotes does not reflect the proliferation of one of the enzyme-expressing cell types (59), which would have resulted in enhanced expression of other enzymes. The lower evening ACTH level in the face of similar corticosterone concentrations suggests altered induction kinetics of the circadian corticosterone peak with accentuated feedback inhibition on pituitary corticotrophs or hypothalamic neurons. Our findings highlight overlapping and distinct molecular pathways regulated by SF-1 and DP103. 1) Dp103-null mice die well before the initial expression of SF-1, which occurs at mouse embryonic d 9 (36,60). 2) Although both DP103 and SF-1 are highly expressed in the gonads and adrenal glands, their expression pattern revealed marked differences. Whereas ovarian DP103 and SF-1 are both expressed in follicular cells and the corpus luteum, DP103 is highly expressed in oocytes, which do not express SF-1 (34,35,38). In the testis, DP103 protein is highly expressed in germ cells, whereas SF-1 is predominantly expressed in Leydig and Sertoli cells (36). In the adrenal gland, both proteins are expressed in the cortex, but DP103 is also expressed in the medulla. 3) The level of expression of several of the steroidogenic enzymes that are regulated by SF-1 was unchanged by DP103 haploinsufficiency. Interestingly, we previously showed that overexpression of DP103 attenuated SF-1-induced Cyp11a1 promoter activity in vitro (19), yet the mRNA level of this rate-limiting steroidogenic enzyme was unchanged in Dp103 heterozygote mice. Together, our data do not illuminate a discrete pathway in which DP103 might negatively regulate the transcriptional activity of SF-1. We also do not know whether DP103 haploinsufficiency during gonad development might stimulate SF-1-dependent ovarian cell proliferation and growth, as has been suggested in adrenocortical cells that overexpress SF-1 (61). It is also possible that the level of DP103 in heterozygous mice is sufficient for repression of SF-1 or that a compensatory mechanism for DP103 haploinsufficiency is up-regulated. Last, we cannot rule out the possibility that Dp103+/− mice could perform differently from wild-type mice under conditions that challenge reproductive performance. Acknowledgments We thank Elena Sadovsky for technical support and Lori Rideout for assistance during preparation of the manuscript. Footnotes The project described was supported by Grant R01 HD37571 (to Y.S.) from the National Institute of Child Health and Human Development. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Child Health and Human Development or the National Institutes of Health. Disclosure Statement: J.M., X.Y., Q.O., L.J., P.A., and Y.S. have nothing to declare. L.J.M. consults as a grant reviewer for the Burroughs Wellcome Fund. First Published Online February 7, 2008 Abbreviations: CEC, Cornified epithelial cells; DP103, DEAD-box protein-103; EGFP, enhanced green fluorescent protein; ES, embryonic stem; NEC, nucleated epithelial cells; PMN, polymorphonuclear cells; SF-1, steroidogenic factor-1, SMN, survival motor neuron; ZGA, zygotic gene activation. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||
Recent Prog Horm Res. 2002; 57():19-36.
[Recent Prog Horm Res. 2002]Rev Reprod. 2000 Sep; 5(3):136-42.
[Rev Reprod. 2000]Nucl Recept. 2003 Sep 18; 1(1):8.
[Nucl Recept. 2003]Cell. 2005 Feb 11; 120(3):343-55.
[Cell. 2005]Mol Cell. 1999 Apr; 3(4):521-6.
[Mol Cell. 1999]Mol Cell Biol. 2003 Jan; 23(1):414-23.
[Mol Cell Biol. 2003]Mol Cell Biol. 2005 Mar; 25(5):1879-90.
[Mol Cell Biol. 2005]J Biol Chem. 2004 Mar 5; 279(10):9056-63.
[J Biol Chem. 2004]Biochem Biophys Res Commun. 2005 Oct 28; 336(3):876-81.
[Biochem Biophys Res Commun. 2005]Cell. 2002 Apr 19; 109(2):169-80.
[Cell. 2002]Nat Genet. 1998 Oct; 20(2):123-8.
[Nat Genet. 1998]Mol Hum Reprod. 2007 Apr; 13(4):273-9.
[Mol Hum Reprod. 2007]J Clin Endocrinol Metab. 2005 Jul; 90(7):4267-75.
[J Clin Endocrinol Metab. 2005]Methods. 2001 Dec; 25(4):402-8.
[Methods. 2001]Biol Reprod. 1982 Sep; 27(2):327-39.
[Biol Reprod. 1982]Proc Natl Acad Sci U S A. 2000 Aug 1; 97(16):9317-22.
[Proc Natl Acad Sci U S A. 2000]Mol Cell Biol. 2003 Jan; 23(1):414-23.
[Mol Cell Biol. 2003]Mol Cell Biol. 2005 Mar; 25(5):1879-90.
[Mol Cell Biol. 2005]Mol Endocrinol. 1993 Jul; 7(7):852-60.
[Mol Endocrinol. 1993]Mol Endocrinol. 1994 May; 8(5):643-53.
[Mol Endocrinol. 1994]Mol Endocrinol. 1994 May; 8(5):654-62.
[Mol Endocrinol. 1994]Dev Biol. 1992 Feb; 149(2):457-62.
[Dev Biol. 1992]Mech Dev. 1992 Feb; 36(3):129-39.
[Mech Dev. 1992]Dev Biol. 1997 Jan 15; 181(2):296-307.
[Dev Biol. 1997]Dev Genet. 1998; 22(1):31-42.
[Dev Genet. 1998]Hum Reprod Update. 2002 Jul-Aug; 8(4):323-31.
[Hum Reprod Update. 2002]Mol Cell Biol. 2003 Jan; 23(1):414-23.
[Mol Cell Biol. 2003]Mol Hum Reprod. 2007 Apr; 13(4):273-9.
[Mol Hum Reprod. 2007]Genes Dev. 2002 Mar 15; 16(6):720-8.
[Genes Dev. 2002]Curr Biol. 2005 Dec 6; 15(23):2149-55.
[Curr Biol. 2005]FASEB J. 2007 Mar; 21(3):656-70.
[FASEB J. 2007]Proc Natl Acad Sci U S A. 2005 Nov 29; 102(48):17372-7.
[Proc Natl Acad Sci U S A. 2005]Genes Dev. 2007 May 1; 21(9):1086-97.
[Genes Dev. 2007]Hum Mol Genet. 2005 Jun 15; 14(12):1605-11.
[Hum Mol Genet. 2005]Mol Cell Biol. 2003 Jan; 23(1):414-23.
[Mol Cell Biol. 2003]Mol Cell Biol. 2005 Mar; 25(5):1879-90.
[Mol Cell Biol. 2005]Mol Endocrinol. 1994 May; 8(5):654-62.
[Mol Endocrinol. 1994]Dev Dyn. 2001 Aug; 221(4):443-53.
[Dev Dyn. 2001]Mol Endocrinol. 1993 Jul; 7(7):852-60.
[Mol Endocrinol. 1993]Mol Endocrinol. 1994 May; 8(5):643-53.
[Mol Endocrinol. 1994]Mol Cell Endocrinol. 2003 Sep 30; 207(1-2):39-45.
[Mol Cell Endocrinol. 2003]